Research groups worldwide are trying to make immunogens intended to elicit neutralizing antibody responses as part of a prophylactic vaccine to counter the spread of HIV-1. The relative merits of different designs can only be gauged properly through comparative studies, and particularly by evaluating human or animal antisera under identical, or comparable, conditions. Hence there is a need for assay standardization and for the creation of a centralized testing facility that could distribute consensus protocols and reagents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Letvin, N.L. & Walker, B.D. Nat. Med. 9, 861–866 (2003).
McMichael, A.J. & Hanke, T. Nat. Med. 9, 874–880 (2003).
Burton, D.R. et al. Nat. Immunol. 5, 233–236 (2004).
Collis, A.V., Brouwer, A.P. & Martin, A.C. J. Mol. Biol. 325, 337–354 (2003).
Wu, T.T., Johnson, G. & Kabat, E.A. Proteins 16, 1–7 (1993).
Parren, P.W.H.I. & Burton, D.R. Adv. Immunol. 77, 195–262 (2001).
Klasse, P.J. & Sattentau, Q.J. J. Gen. Virol. 83, 2091–2108 (2002).
Mascola, J.R. Vaccine 20, 1922–1925 (2002).
Dreyer, K. et al. AIDS Res. Hum. Retroviruses 15, 1563–1571 (1999).
Spenlehauer, C., Gordon, C.A., Trkola A. & Moore, J.P. Virology 280, 292–300 (2001).
Wei, X. et al. Antimicrob. Agents Chemother. 46, 1896–1905 (2002).
Mascola, J.R. et al. J. Virol. 76, 4810–4821 (2002).
Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Proc. Natl. Acad. Sci. USA 100, 4144–4149 (2003).
Klausner, R.D. et al. Science 300, 2036–2039 (2003).
Moore, J.P., Parren, P.W.H.I. & Burton, D.R. J. Virol. 75, 5721–5729 (2001).
Pugach, P. et al. Virology 321, 8–22 (2004).
Derdeyn, C.A. et al. Science 303, 2019–2022 (2004).
D'Souza, M.P., Livnat, D., Bradac, J.A. & Bridges, S.H. J. Infect. Dis. 175, 1056–1062 (1997).
Acknowledgements
We thank J. Mascola, D. Montefiori and R. Wyatt for helpful comments. Research on HIV-1 vaccine projects in the authors' laboratories is supported by the US National Institutes of Health and by the International AIDS Vaccine Initiative.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moore, J., Burton, D. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med 10, 769–771 (2004). https://doi.org/10.1038/nm0804-769
Issue Date:
DOI: https://doi.org/10.1038/nm0804-769
This article is cited by
-
Moving candidate vaccines into development from research: lessons from HIV
Immunology & Cell Biology (2009)
-
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
Nature Medicine (2007)
-
Combination DNA plus protein HIV vaccines
Springer Seminars in Immunopathology (2006)